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Abstract
Objective: To evaluate the effectiveness and safety of heat-killed M.vaccae added to chemotherapy of never-treated
tuberculosis (TB) patients.
Methods: The databases of Medline, Embase, Biosis, Cochrane Central Register of Controlled Trials, SCI, CBM, VIP and CNKI
were searched. Randomized controlled trials (RCT) and Controlled clinical trials (CCT) comparing M.vaccae with or without a
placebo-control injection as adjuvant therapy in the chemotherapy of never-treated TB patients were included. Two
reviewers independently performed data extraction and quality assessment. Data were analyzed using RevMan 5.0 software
by The Cochrane Collaboration.
Results: Fifty four studies were included. At the end of the follow-up period, Pooled RR (Risk Ratio) and its 95% CI of sputum
smear conversion rate were 1.07 (1.04, 1.10) in TB patients without complications, 1.17 (0.92, 1.49) in TB patients with
diabetes mellitus, 1.02 (0.94, 1.10) in TB patients with hepatitis B, and 1.46 (0.21, 10.06) in TB patients with pneumosilicosis.
In elderly TB patients the RR was 1.22 (1.13, 1.32). Analysis of each time point during the follow-up period showed that
M.vaccae could help to improve the removal of acid-fast bacilli from the sputum, and promote improvement of radiological
focal lesions and cavity closure. Compared with the control group, the differences in levels of immunological indicators of
Th1 such as IL-2 and TNF-a were not statistical significant (P=0.65 and 0.31 respectively), and neither was that of IL-6
produced by Th2 (P=0.52). An effect of M.vaccae of prevention of liver damage was found in TB patients with hepatitis B
(RR 0.20 and 95% CI (0.12, 0.33). No systemic adverse events were reported.
Conclusion: Added to chemotherapy, M.vaccae is helpful in the treatment of never-treated TB patients in terms of
improving both sputum conversion and X-ray appearances.
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Introduction
Inactivated M.vaccae (MV), a heat-killed vaccine derived from a
non-tuberculosis mycobacterium, is the only immunotherapeutic
agent recommended by WHO in the Tuberculosis Strategic
Development Plan of 1991 [1]. Tuberculosis (TB) is characterized
by the combined activity of T-helper type 2 (Th2) lymphocytes
with T-helper type 1 (Th1) lymphocytes [2]. M.vaccae can enhance
cellular immune function through induction of Tr (regulatory T
lymphocytes) [3] and by promoting macrophage effects. It was
found in an earlier study that treatment of TB patients with
M.vaccae can enhance Th1 and switch off the Th2 response [4]. As
Th1 lymphocytes can provide protective immunity [2], it is crucial
that immunotherapy for TB should swing the Th1/Th2 balance.
Systematic reviews, which aimed to investigate M.vaccae immuno-
therapy as an adjunct to anti-TB treatment in previously treated
patients [5] and multidrug-resistant tuberculosis (MDR-TB)
patients [6], and as a preventive agent for people at high risk [7]
have already been published and show that M.vaccae is safe and
well tolerated, and can shorten the treatment course and promote
conversion of clinical indicators. However, no systematic review is
available for its use in never-treated TB patients, who are an
important group of people for TB control and prevention in the
community. Diagnosis and treatment of these people are essential
to TB control as they are a source of infection until they die. From
January to September 2009, about 750,000 TB patients were
discovered and treated in China, among whom never-treated
patients accounted for almost a half (340,000) [8]. In this paper,
we explore the effects of M.vaccae as adjuvant therapy for never-
treated TB patients.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e23826There are two available preparations of M.vaccae, the original
one developed in the U.K. is prepared from the rough variant of a
selected strain, grown on a non-antigenic medium until the
stationary phase. The washed organisms are suspended in borate-
buffered saline, diluted to 10 mg (wet-weight)/ml, autoclaved and
stored in vials for use. This reagent is either administered by
intradermal injection or by mouth as capsules. The dose by either
route is 1 mg of killed bacilli. The second, prepared in China, is
made from the type strain of M.vaccae. It is 22.5 mg powder stored
in vials for use, administered by intramuscular injection.
Methods
1. Study eligibility criteria (PICOS)
1.1 Participants (P). Never-treated TB patients with sputum
smear positive for acid-fast bacilli or culture positive for
Mycobacterium tuberculosis (M. tuberculosis).
1.2 Intervention (I). Intervention: Inoculation with
M.vaccae as an adjunct to standard anti-TB treatment.
1.3 Control (Comparison) (C). Control: Injection with a
placebo plus anti-TB treatment, or anti-TB treatment alone.
1.4 Outcome (O). Primary outcomes: Conversion to sputum
smear or culture negativity. Secondary outcomes:
N Change in clearance of X-rays: complete absorption; marked
absorption (focal change.1/2); absorption (focal change,1/
2); unchanged; or deterioration.
N Cavity closure rates: closure; unchanged;enlargement.
N Immunological indicators: changes in levels of markers of
Th1(Tumor necrosis factor alpha [TNF-a], interferon-gamma
[IFN-c], interleukin-2 [IL-2]) and Th2 (interleukin-4 [IL-4],
interleukin-6[IL-6]).
N Adverse events: such as local induration at the injection site,
sore arm, skin breakdown, fever.
1.5 Study design (S). The studies selected for analysis were
either Randomized controlled trails (RCT) or controlled clinical
trials (CCT) without randomization. We did not use these terms as
a restriction when searching the database, but filtered the articles
by reading the abstract (and when necessary, the full length article,
or by contacting the authors) in order to classify the studies.
2. Search strategy
English databases of the Cochrane Controlled Trials Register,
MEDLINE, EMBASE, BIOSIS, SCI and Chinese databases of
CBM, CNKI, VIP were searched till December 2010 using
keywords of Mycobacterium vaccae and tuberculosis, without
limitation of language, and the references of eligible studies were
also searched. When the full length article were not available form
the databases, we contacted the author asking for it.
3. Quality assessment in individual studies
Two reviewers (Q-fei Chen, S-miao Wu) independently
performed data extraction and quality assessment. Four items
were used to assess the quality of included studies based on
Cochrane Collaboration recommended criteria: Adequate se-
quence generation, Allocation concealment, Blinding, and ad-
dressing the problem of incomplete outcome data.
4. Risk of bias across studies
The selective reporting within studies was assessed by answering
whether the results were fully reported as the study was pre-
specified (for example, if all the results were reported at all follow-
up time points).
5. Statistical analysis
Statistical analysis was carried out using Revman 5.0 software. All
studies were grouped by TB patients with different complications
without consideration of variations in the anti-TB treatment regimens.
Subgroups were delineated according to different time points during
follow-up period. The heterogeneity test for the included studies was
applied and p values of less than 0.05 were considered as statistical
significance. The fixed effect model was applied in subgroups without
heterogeneity, and in the others the random effect model was applied.
G61.96SG (G-Geometric mean, SG -standard error of geometric
mean) was used to describe continuous variables and Risk Ratios (RR)
and their 95% confidence interval (95%CI) were used for binary
variable. Results were described for data that could not be combined
and for safety evaluation.
Results
1. Description of studies and quality assessment
The initial search extracted 1182 articles, and after selection, 54
met the inclusion criteria among which 48 were in Chinese and 6
in English (Figure 1).
Table S1 shows the characteristics of the included studies.
Forty eight trials [9–56] were conducted in China and six [57–
62] were carried out in Romania, South Africa, South American
(Argentina), Uganda, and Zambia. Trials carried out in China
included subjects with diabetes mellitus [39–45], hepatitis B [46–
48] and pneumoconiosis [49,50]. Studies in other countries
included TB patients who were infected with the Human
Immunodeficiency Virus (HIV) [58,61].
The ages of the TB patients (excluding studies specifically on
older patients [51–56]) ranged from 18 to 65. The TB patients in
the studies of older patients [51–56] were all above 65 years.
In trials carried out in China, patients were inoculated with
multiple doses of M.vaccae. Immunotherapy was generally
administered as a dose of 22.5 mg per 1or 2 weeks and the
duration of administration and the interval between doses varied.
In trials outside China, a single dose of 0.1 ml of heat-killed
M.vaccae containing 10
9 organisms [57–61] was used, and in still
others, three doses [62] were applied. The time of initiation of
administration of M.vaccae in relation to chemotherapy varied
between studies: 19 articles reported that M.vaccae was first
inoculated at the end of the 2
nd week, 7 articles at the end of the 1
st
week, and 7 articles on the 1
st day.
According to the Guidelines for the Implementation of
Tuberculosis Control in China, the standard anti-TB treatment
regimen used in China was 2 months of daily Isoniazid, Rifampicin,
Pyrazinamide, with or without Streptomycin, followed by 4 months
of Isoniazid and Rifampicin (2HRZE(S)/4HR) , see Table S1.
Table S2 shows the quality assessment of the included studies. The
quality of the trials conducted abroad was higher than those carried
out in China. After contacting the author, only 2 articles [32,49]
carried out in China got ‘‘yes’’ in ‘‘Adequate sequence generation’’
and no articles in China got ‘‘yes’’ in Allocation concealment.Among
6 studies carried out abroad, 5 [57,58,60–62] got ‘‘yes’’ in ‘‘Adequate
sequence generation’’, 5 [57,58,60–62] got ‘‘yes’’ in ‘‘blinding’’ and 3
[58,60,61] got ‘‘yes’’ in ‘‘Allocation concealment’’.
The results at all follow-up time points which was pre-specified
were fully reported in included studies. But the time points for the
results of interest varied across studies, see Table S3, Table S4,
and Table S5.
2. Primary outcomes of the effects of intervention
2.1 Never-treated TB patients without complications. .
Sputum smear conversion rate: Figure 2 shows the conversion rates
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recipient groups compared with the control groups receiving
chemotherapy, with or without a placebo injection. The random
effect model was applied at the end of the follow-up period (1–6
month after the first MV injection), the pooled RR and its 95% CI
was 1.07 (1.04, 1.10), with statistical significance (P,0.0001). The
pooled RR and its 95% CI of each follow-up month (1 to 6 months)
are shown in Table S3. Although the anti-TB treatment regimens
were different, the overall effects were all statistically significant
through one to six months of follow-up (P#0.05).
Sputum culture negative conversion rate: In eight trials
[12,14,16,18,57,60–62] the sputum culture negative conversion
rate was determined. The pooled RR and 95% CI at the end of
the follow-up period were 1.03 (0.99, 1.06), without statistical
significance (P=0.12) (Figure 3). Further analysis of each follow-
up time point at 1,2 4 and 6 months after injection showed that
meta analysis at 1 and 2 months were statistically significant
(P,0.05) but not significant at 4 and 6 months (P=0.87 and 0.12
respectively) , see Table S3.
2.2 Sputum smear conversion rates of TB patients with
complicating medical conditions. TB patients with diabetes
mellitus: Six trials [39,41–45] were based on TB patients with
diabetes mellitus, with follow-ups at 1, 2, 3 and 6 months. The
random effect model was applied at the completion of follow-ups.
The pooled RR and 95% CIs were 1.17 (0.92, 1.49), without
statistical significance (P=0.20) (Figure 4). Meta analysis of
sputum smear AFB2 rate for each follow-up period is shown in
Table S3. The overall effects of 2, 3 and 6 months were statistically
significant (P=0.009, 0.0001 and 0.01 respectively), while, it was
not statistically significant at 1 month (P=0.08).
TB patients with hepatitis B: In three trials [46–48] in which the
smear AFB2 rate at 6 months was determined, the pooled RR
and 95% CI were 1.02(0.94,1.10), the P value of the overall effect
was 0.65 without statistical significance , see Table S3.
TB patients with pneumosilicosis: Two trials [49,50] reported
the smear AFB2 rate at 3 months and meta-analysis showed that
pooled RR and 95%CIs were 1.46(0.21,10.06), without statistical
significance (P=0.70) , see Table S3.
2.3 Sputum smear negative conversion rates of elderly TB
patients. Six trials [51–56] reported the immunotherapyeutic
effects of M.vaccae on elderly TB patients. Their combined result
at completion of the follow-up period is shown in Figure 5. The
fixed effect model was applied and the pooled RR and 95% CI
were 1.22 (1.13, 1.32). The test for overall effect was statistically
significant (P,0.00001). The subgroup results for each follow-up
time point are shown in Table S3, where it can be seen that the
overall effect at each follow-up time point was statistically
significant (P,0.05) (except at 3 months, P=0.61).
3. Secondary outcomes
3.1 Meta analysis of radiological focal lesion changes and
cavity closure rates. Table S4 shows that both complete
absorption and marked absorption were significantly improved in
M.vaccae recipients at 2, 4 and 6 month follow ups in never-
treated TB patients without complications (P,0.05).
In TB patients with diabetes mellitus, marked absorption and
absorption of focal lesions were statistically significant at the 6 month
follow up, and in TB patient with HBsAg
+, marked absorption of
focal lesions was statistically significant at 6 months. In studies of
elderly TB patients, marked absorption and absorption of lesions
were statistically significant at 2, 4 and 6 month follow-ups.
Table S5 shows that cavity closure rates were significantly
different between treatment groups at 2, 4 and 6 month follow-up
periods in never-treated TB patient without complications
(P,0.05). In TB patients with diabetes mellitus or HBsAg
+,
closure of cavities was significant at the 6 month follow-up. In TB
patient with pneumosilicosis, the cavity closure rate was significant
at the 6 month follow-up. In elderly TB patients, the difference in
cavity closure between the two treatment groups was significant at
the 2 and 4 months follow-up, but not significant at the 6 month
follow-up.
3.2 Immunological features. Immunological factors induced
by Th1 lymphocytes: Serum (or plasma) IL-2: values were reported in
2 studies [10,14]. It was found that IL-2 increased in the
immunotherapy group compared with control group, but did not
reach statistical significance in either study (P.0.05, data not shown).
Also there was no statistical difference between the immunotherapy
and placebo groups of the 2 studies, when they were combined
(P=0.65), see Table S6.
IFN-c: In two trials [58,60] it was shown that IFN-c levels were
elevated in the immunotherapy group, being statistically signifi-
cant in one study; the other only mentioned that IFN-c was
Figure 1. Flow diagram of study searching and selection process.
doi:10.1371/journal.pone.0023826.g001
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difference was statistically significant.
TNF-a: In four trials [10,59,60,62] differences in TNF-a
levels between immunotherapy and control groups were
reported. In one study [60] the level had decreased at the
end of 2 months, but detailed data were not given. In another
study [62] levels of TNF-a in the supernates of unstimulated
polymorphonuclear leucocytes and monocytes fell steeply and
significantly (p,0.05) in recipients of M.vaccae,w h e r e a st h e y
changed minimally in placebo recipients. When the data were
Figure 2. Meta analysis of sputum smear negative conversion rates in TB patients. Vertical line indicates no difference between the
compared two groups (MV vs. control). Squares indicate point estimates of risk ratio (RR) in each individual study, the size of the squares indicates the
weight of the corresponding study in the meta-analysis, 95%CIs of point estimates are shown by horizontal lines. Pooled RR and its 95%CI are shown
by diamond shape. (It is the same in Figures 3, 4, 5, 6.)
doi:10.1371/journal.pone.0023826.g002
Figure 3. Meta analysis of sputum culture negative conversion rate in TB patients at the end of following up period.
doi:10.1371/journal.pone.0023826.g003
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S6.
Immunological factors induced by Th2 lymphocytes: IL-4: two
trials [59,62] reported the level of IL-4 and both of them showed a
significant difference between the immunotherapy group and
control group (data not shown).The immunotherapy had signif-
icant effect of reducing the grossly raised level of IL-4 on admission
in newly diagnosed TB patients after one [59], or one, two and
three [62] month(s) administration (P,0.001 in both studies),
suggesting that the immunotherapy helped to reduce the influence
of Th2 to the benefit of the patients.
IL-6: Data from 2 trials [10,14] were combined, and the results of
meta analysis showed that there was no statistical significance between
the immunotherapy and control groups (P=0.52), see Table S6.
3.3 Adverse events. None of the included studies reported
any systemic adverse events, however, there were local effects
existed, and the most frequently mentioned adverse events were
local induration at the injection site [9–12,14,18,19,22,27–
29,31,33–35,38,39,43,45,49–51,54–56,58,60], fever [9–12,14,18,
19,31,33,43,45,50,51,54,55] and sore arm/pain [29,33,45,61].
For TB patients co-infected with hepatitis B, the meta analysis
of liver damage rates shows that M.vaccae has protective effects on
liver function (P,0.05)(Figure 6).
Discussion
Heat-killed M.vaccae is a new kind of immune modulator which,
in the case of TB, can replace immunopathology with protective
antibacterial immunity [58] and enhance immunoregulation
through induction of T-regulatory cells [3]. Although anti-TB
chemotherapy can kill most of the rapidly replicating bacilli within
days, a ‘‘persister’’ population of slowly replicating or dormant
organisms needs long-term treatment for at least 6 months [63],
and if treatment is stopped early, there is a high probability of
relapse. M.vaccae can shorten the duration of therapy and induce
immune responses that kill the persister organisms [3,58],
accelerate sputum conversion and promote absorption of lesions
and healing of cavities. ‘‘The guidelines for implementation of
Tuberculosis Control Program in China’’ requires that never-
treated TB patients should have repeated sputum smear
examinations in their follow-up period at the end of the 2nd,
5th and 6th month. This shows that the overall RRs of smear
AFB- rates are greater than one, and with statistical significance,
regardless of chemotherapy used.
Although the meta-analysis of sputum culture conversion rates
does not show any statistical significance at the end of following up
period, the results at 1 and 2 months of follow-up show a
significant difference, implying that M.vaccae can help to improve
sputum conversion to AFB2 in patients without complicating
medical conditions. An important point to note is that chemo-
therapy alone is very successful at removing AFB from the third
month onwards, giving almost no chance of showing any
improvement due to an additional therapy at the later time-
points. For TB patients co-affected with diabetes mellitus, hepatitis
B or pneumosilicosis, the overall effect does not achieve statistical
significance. The results show that the effect of M.vaccae is better in
Figure 4. Meta analysis of sputum smear negative conversion rates in TB patients with diabetes at the end of follow-up period.
doi:10.1371/journal.pone.0023826.g004
Figure 5. Meta analysis of sputum smear negative conversion rates in elderly TB patients at the end of follow-up period.
doi:10.1371/journal.pone.0023826.g005
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with such conditions. Several factors may account for it: firstly, the
total research subjects with complicating medical conditions were
much less than those without, which resulted in a false negative
estimation; Secondly, the limited subjects were subjected to several
different follow-up time points, which further reduced the sample
size; Thirdly, the trials targeted at the newly-diagnosed TB
patients co-affected with hepatitis B or pneumosilicosis had only
results at 3 months or later, which gives almost no chance of
showing any bacteriological improvement (see above); And finally,
it’s really the case and the mechanism is needed to be determined.
As for focal changes and cavity closures on X-ray, the results show
that M.vaccae can help to promote absorption of lesions (both
complete and marked absorption) and cavity closure. M.vaccae is
safe and well tolerated without any systemic adverse events
reported in the included studies. A potentially important novel
feature reported in this paper is that M.vaccae has a protective effect
on liver function in those with TB complicated by infectious
hepatitis. Is it the true effect, or, just a distorted estimate because of
the bias (only three trials with low quality are included)? More
studies of high quality are warranted.
The quality assessment showed that in general, the non-Chinese
clinical trials had better quality than those carried out in China,
but it did not introduce any heterogeneity in sputum culture
negative conversion rate, nor did it substract any importance to
the overall results.
Our study includes the reports specially targeted at never-
treated TB patients, without restriction on language (48 out of 54
were published in Chinese), with a total number of 7149 TB
patients involved. The study provides pooled estimates in different
groups with and without complicating co-factors. The conclusion
of this study is not consistent with study de Bruyn G 2003 [64],
which only included studies in English and did not specifically
target at never-treated TB patients. There was a review [3] of all
studies on immunotherapy with M.vaccae, as prepared in England
and including some conducted under suboptimal conditions, but it
was not a systematic review and merely demonstrated the results of
each study without pooled estimates and, furthermore, it did not
target specially at never-treated TB patients.
There are several limitations of our study: first, the follow-up
period was not long enough to obtain the results of long-term
effects, for example, recurrence, drug resistance, and so on, and
the follow-up time points varied across studies. Secondly,
immunological characteristics were only determined in a minority
of the studies so that the effect of M.vaccae on Th1/Th2 levels in
TB remains to be further confirmed and thirdly, the multi-dose use
of M.vaccae in all trials conducted in China was not standardised,
so the optimum dosing schedule has still to be determined.
Conclusion: M.vaccae is a well-tolerated and helpful addition to
treatment for never-treated TB patients in terms of significantly
improved sputum conversion and radiological appearances.
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